Summary of Clinical Use

Secukinumab is approved by the US FDA for the treatment of plaque psoriasis. Secukinumab also met its clinical endpoints in Phase 2I clinical trial for ankylosing spondylitis (NCT01649375) [1], and was FDA approved for this indication and psoriatic arthritis [7-8] in January 2016. The antibody is also in Phase 2 clinical trial for multiple sclerosis (NCT01874340) based on results from experiments in an animal model of the disease (experimental autoimmune encephalomyelitis, EAE) and in vitro human cell assays [3].

Mechanism Of Action and Pharmacodynamic Effects

Secukinumab targets proinflammatory interleukin (IL)-17A [5] which is released by T helper 17 cells [11], and is a validated molecular target for the treatment of chronic immune diseases [10]. Antibody neutralisation of circulating IL-17A reduces symptoms in autoimmune diseases such as plaque psoriasis [6,9], rheumatoid arthritis (note that clinical trial results have not shown significant improvement over placebo [4]), and chronic noninfectious uveitis.

External links

For extended ADME data see the following: Electronic Medicines Compendium (eMC) Drugs.com European Medicines Agency (EMA)